Year-end Sale % OFF 
Abstract
Yttrium-90 ibritumomab is a recent option in the therapeutic armamentarium for follicular, indolent, or transformed malignant non-Hodgkin lymphoma. Its administration depends on the normal biodistribution of indium-111 ibritumomab on whole-body scintigraphy. Although tumor assessment with an indium-111-1a-beled monoclonal antibody is not an absolute necessity, biodistribution imaging may show extranodal soft tissue involvement of non-Hodgkin lymphoma. A case with an upper extremity lesion is presented in correlation with magnetic resonance examination.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
